S.B. 78
         PHARMACY ACT AMENDMENTS

Senate Committee Amendments

Amendment 1 February 20, 2013 12:51 PM



Senator Evan J. Vickers proposes the following amendments:

1.    Page 17, Lines 501 through 509 :    

             501          (7) A pharmacist or pharmacy intern who substitutes an interchangeable biosimilar
             502      product for a prescribed biological product shall
  communicate the substitution to the purchaser. The interchangeable biosimilar product container shall be labeled with the name of the interchangeable biosimilar product dispensed, and the pharmacist, pharmacy intern, or pharmacy technician shall indicate on the file copy of the prescription both the name of the prescribed biological product and the name of the interchangeable biosimilar product dispensed in its place.            {   :

             503          (a) communicate the substitution to the purchaser;
             504          (b) ensure that the interchangeable product container is labeled with the name and the
             505      manufacturer of the interchangeable biosimilar product dispensed; and
             506          (c) indicate on the file copy of the prescription:
             507          (i) the name and the manufacturer of the prescribed biological product; and
             508          (ii) the name and the manufacturer of the interchangeable biosimilar product dispensed
             509      in place of the prescribed biological product.   }

2.    Page 17, Lines 510 through 516 :    

             510          (8) A pharmacist or pharmacy intern who substitutes an interchangeable biosimilar
             511      product for a prescribed biological product shall:
             512          (a) notify the prescriber in writing
  , by fax, telephone, or electronic transmission       of the substitution, as soon as practicable, but not

             513      later than three business days after dispensing the interchangeable biosimilar product in place
             514      of the prescribed biological product; and
             515          (b) include the name and manufacturer of the interchangeable biosimilar product
             516      substituted.

3.    Page 17, Lines 517 through 521 :    

             517          
{   (9) The pharmacist or pharmacy intern shall:

             518          (a) retain a written record of the substitution for at least five years; and
             519          (b) include the name and manufacturer of the interchangeable product substituted.   }
             520          
{   (10)   }        (9)       A licensed medical practitioner who fails to specify that no substitution is

             521      authorized does not constitute evidence of negligence.

Page 1 of 1
LRGC ajacobson ajacobson